跳至主要内容
临床试验/ACTRN12622000091707
ACTRN12622000091707尚未招募未知

Effect of a mobile health program optimised with artificial intelligence (My Intelligent Cardiac Assistant—MICArdiac) on Systolic Blood Pressure and other cardiovascular risk factors in adults with high blood pressure: a multi-centre randomised controlled trial

niversity of Sydney0 个研究点目标入组 500 人开始时间: 2022年1月24日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
35 Years 至 o limit(—)
性别
All

入选标准

  • Participants are eligible if they meet all 3 of the following criteria and have no exclusion criteria.
  • 1.Adults 35 years and over
  • 2.Own a compatible smartphone – iPhone 5 onwards (iOS 10 and higher) or Android (6.0 and higher).
  • 3.Uncontrolled hypertension/high blood pressure (1 of the following):
  • a)Known hypertension AND at least one recorded measure of SBP equal or above to 140mmHg and/or DBP equal or above to 90 mmHg in the last 12 months; OR
  • b)At least one recorded measure of SBP equal or above to 160mmHg and/or DBP equal or above to 100 mmHg in the last 12 months; OR
  • c)At least two recorded measures of SBP equal or above to 140mmHg and/or DBP equal or above to 90 mmHg in the last 12 months.

排除标准

  • History of cardiovascular disease, including peripheral artery disease, heart failure, coronary heart disease, stroke
  • Have a pacemaker, defibrillator or other electrical implant not suited for use with provided wireless monitoring devices.
  • Unable to use wearable/wireless monitoring devices provided
  • Unable to complete the study procedures or follow-up
  • Unable to understand sufficient written English to provide informed consent
  • Unable to provide informed consent
  • Any condition that in the opinion of the responsible physician or investigator renders the patient unsuitable for the study (e.g. severe disability or significant memory or behavioural disorder)

研究者

相似试验

Effect of a mobile health intervention optimised... | 临床试验